📊 HIND Key Takeaways
Is Vyome Holdings, Inc (HIND) a Good Investment?
Vyome is a pre-commercial pharmaceutical company with only $31.6K in revenue but -$1.4M quarterly operating cash burn, yielding a -3048% net margin. Despite 24% revenue growth and a solid cash position of $8.8M, the current burn rate suggests only 2 years of runway before capital infusion or dilution becomes necessary. Negative profitability across all metrics, zero insider buying activity, and a business model that remains fundamentally unproven present substantial risk.
Vyome Holdings generates minimal revenue relative to its operating cost base, resulting in extremely negative operating and net margins alongside deeply negative ROE/ROA. Liquidity is adequate near term (current ratio ~2x and ~$5M cash), but persistent operating cash burn and losses imply a high likelihood of additional financing. Modest revenue growth and solid gross margin do not offset the scale gap and cash burn risk.
Why Buy Vyome Holdings, Inc Stock? HIND Key Strengths
- Strong gross margin of 52.7% suggests underlying product economics may be viable at scale
- Excellent liquidity position (4.27x current ratio, 3.08x quick ratio) provides near-term operational flexibility
- Revenue growth of 24.4% YoY indicates early commercial traction
- High gross margin suggesting potential unit economics if scaled
- Near-term liquidity supported by ~2x current ratio and ~$5M cash
- Positive equity base with moderate leverage (D/E ~0.8x)
HIND Stock Risks: Vyome Holdings, Inc Investment Risks
- Unsustainable cash burn rate of -$1.4M quarterly against $8.8M cash reserves limits runway to ~2-2.5 years
- Catastrophically negative operating margins (-3576.8%) and net margins (-3048.1%) indicate unproven business model at revenue scale
- Pre-commercial stage business model with minimal $31.6K revenue base creates binary risk profile; dilution or failed pipeline likely
- Severe and persistent operating losses with extreme negative margins
- Negative free cash flow and short runway imply financing/dilution risk
- Execution risk in scaling revenue from a very small base, including going-concern risk
Key Metrics to Watch
- Quarterly cash burn rate and cash runway extension
- Revenue acceleration trajectory and path to breakeven
- Operating cash flow improvement or further deterioration
- Quarterly operating cash flow and cash runway (cash vs burn)
- Revenue growth relative to operating expenses (OPEX vs revenue)
Vyome Holdings, Inc (HIND) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.27x current ratio provides a solid financial cushion.
HIND Profit Margin, ROE & Profitability Analysis
HIND vs Healthcare Sector: How Vyome Holdings, Inc Compares
How Vyome Holdings, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vyome Holdings, Inc Stock Overvalued? HIND Valuation Analysis 2026
Based on fundamental analysis, Vyome Holdings, Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vyome Holdings, Inc Balance Sheet: HIND Debt, Cash & Liquidity
HIND Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vyome Holdings, Inc's revenue has grown significantly by 164% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6,001.39 indicates the company is currently unprofitable.
HIND Revenue Growth, EPS Growth & YoY Performance
HIND Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $1.2M | -$1.2M | $-1.85 |
| Q1 2025 | $1.1M | $1.5M | $18.98 |
| Q3 2024 | $2.2M | -$1.6M | $-3.11 |
| Q2 2024 | $2.0M | -$1.6M | $-0.06 |
| Q1 2024 | $1.9M | -$2.2M | $-0.09 |
| Q3 2023 | $2.2M | -$3.5M | $-1.02 |
| Q2 2023 | $2.3M | -$3.5M | $-1.08 |
| Q1 2023 | $2.3M | -$2.7M | $-1.56 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vyome Holdings, Inc Dividends, Buybacks & Capital Allocation
HIND SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vyome Holdings, Inc (CIK: 0001427570)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HIND
What is the AI rating for HIND?
Vyome Holdings, Inc (HIND) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HIND's key strengths?
Claude: Strong gross margin of 52.7% suggests underlying product economics may be viable at scale. Excellent liquidity position (4.27x current ratio, 3.08x quick ratio) provides near-term operational flexibility. ChatGPT: High gross margin suggesting potential unit economics if scaled. Near-term liquidity supported by ~2x current ratio and ~$5M cash.
What are the risks of investing in HIND?
Claude: Unsustainable cash burn rate of -$1.4M quarterly against $8.8M cash reserves limits runway to ~2-2.5 years. Catastrophically negative operating margins (-3576.8%) and net margins (-3048.1%) indicate unproven business model at revenue scale. ChatGPT: Severe and persistent operating losses with extreme negative margins. Negative free cash flow and short runway imply financing/dilution risk.
What is HIND's revenue and growth?
Vyome Holdings, Inc reported revenue of $31.6K.
Does HIND pay dividends?
Vyome Holdings, Inc does not currently pay dividends.
Where can I find HIND SEC filings?
Official SEC filings for Vyome Holdings, Inc (CIK: 0001427570) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HIND's EPS?
Vyome Holdings, Inc has a diluted EPS of $-0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HIND a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Vyome Holdings, Inc has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HIND stock overvalued or undervalued?
Valuation metrics for HIND: ROE of -12.0% (sector avg: 15%), net margin of -3,048.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HIND stock in 2026?
Our dual AI analysis gives Vyome Holdings, Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HIND's free cash flow?
Vyome Holdings, Inc's operating cash flow is $-1.4M, with capital expenditures of $43.0K. FCF margin is -4,681.6%.
How does HIND compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,048.1% (avg: 12%), ROE -12.0% (avg: 15%), current ratio 4.27 (avg: 2).